These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Guigon CJ; Zhao L; Willingham MC; Cheng SY Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818 [TBL] [Abstract][Full Text] [Related]
4. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN. Ramírez-Moya J; Wert-Lamas L; Santisteban P Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884 [TBL] [Abstract][Full Text] [Related]
6. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840 [TBL] [Abstract][Full Text] [Related]
7. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease. Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154 [TBL] [Abstract][Full Text] [Related]
8. FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide. Weidinger C; Krause K; Mueller K; Klagge A; Fuhrer D J Clin Endocrinol Metab; 2011 Sep; 96(9):E1361-71. PubMed ID: 21752881 [TBL] [Abstract][Full Text] [Related]
9. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751 [TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Marquard FE; Jücker M Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230 [TBL] [Abstract][Full Text] [Related]
11. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503 [TBL] [Abstract][Full Text] [Related]
12. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319 [TBL] [Abstract][Full Text] [Related]
13. NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia. Guo D; Teng Q; Ji C Leuk Lymphoma; 2011 Jul; 52(7):1200-10. PubMed ID: 21463127 [TBL] [Abstract][Full Text] [Related]
14. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754 [TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898 [TBL] [Abstract][Full Text] [Related]
16. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452 [TBL] [Abstract][Full Text] [Related]
17. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Li J; Dang Y; Gao J; Li Y; Zou J; Shen L Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539 [TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285 [TBL] [Abstract][Full Text] [Related]
19. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma. Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194 [TBL] [Abstract][Full Text] [Related]
20. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. Lim HJ; Crowe P; Yang JL J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]